Global Poliovirus Vaccine Inactivated Market Size By Type (Human Diploid Cell, Monkey Kidney Cell), By Application (Public, Private), By Region, And Segment Forecasts, 2023 to 2032

The Global Poliovirus Vaccine Inactivated Market was valued at USD 1.4 billion in 2023 and is projected to reach USD 2.6 billion by 2031, expanding at a CAGR of 8.3% during the forecast period of 2023–2031. The market's growth is driven by robust global immunization initiatives, increasing awareness about vaccine-preventable diseases, and governmental and non-governmental support for eradication programs. The inactivated poliovirus vaccine (IPV) plays a crucial role in ensuring safe and effective immunization with minimal risk of vaccine-derived infections, making it a key element in global public health strategies.

Drivers:

1. Global Immunization Programs and WHO Initiatives

Efforts led by organizations like WHO, UNICEF, and Gavi have significantly boosted IPV adoption in national immunization schedules. These campaigns have ensured widespread availability of vaccines in both developed and developing regions.

2. Increasing Focus on Eradicating Polio

Though global cases of wild poliovirus have dropped drastically, complete eradication remains a public health goal. Countries are reinforcing their IPV coverage to replace the oral version, particularly due to risks associated with oral vaccine-derived strains.

3. Favorable Regulatory and Funding Environment

IPV development and distribution are being actively supported by health agencies and governments via expedited approvals, subsidies, and funding through initiatives like the Global Polio Eradication Initiative (GPEI).

Restraints:

1. High Cost of IPV Compared to OPV

Unlike the oral counterpart, IPV is more expensive to manufacture and administer. This cost burden may limit its accessibility in low-income countries without international aid.

2. Cold Chain and Storage Constraints

The requirement for a robust cold chain logistics infrastructure for IPV storage and transport can be a challenge, particularly in remote areas with underdeveloped healthcare facilities.

Opportunity:

1. Integration with Routine Immunization Schedules

Opportunities exist to incorporate IPV into routine infant immunization programs in more countries, especially those transitioning from OPV to IPV-based regimes.

2. Technological Advancements in Vaccine Production

Innovations in inactivation methods and cell-culture techniques are making IPV more scalable and cost-efficient, which could enhance its adoption across broader geographies.

Market by Vaccine Type Insights:

Based on vaccine type, the Conventional Inactivated Poliovirus Vaccine (cIPV) segment held the dominant market share in 2023 due to its long-standing usage and global acceptance. However, the Sabin-strain IPV (sIPV) segment is gaining traction owing to its lower biosafety risks during manufacturing and potential cost-effectiveness.

Market by End-use Insights:

In terms of end-use, Public Health Agencies and Government Vaccination Programs accounted for over 65% of the market share in 2023. This dominance is due to large-scale procurement and administration of IPV under national immunization programs, often funded by international health organizations.

Market by Regional Insights:

Asia-Pacific led the global IPV market in 2023, driven by mass immunization initiatives in countries like India, Bangladesh, and Indonesia. Africa is projected to witness the highest growth rate during the forecast period, as multiple nations scale up IPV deployment to meet global eradication targets. Meanwhile, North America and Europe continue to ensure 100% IPV coverage through strong public health infrastructures.

Competitive Scenario:

Key players in the Global Poliovirus Vaccine Inactivated Market include Sanofi Pasteur, GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Bilthoven Biologicals (Intravacc), AJ Vaccines, and Bio Farma. These companies are leveraging partnerships with international organizations and investing in technological innovation to enhance IPV production and distribution efficiency.

Key Developments:

2023: Serum Institute of India launched an enhanced IPV formulation based on sIPV technology, increasing shelf life and stability.

2024: Sanofi Pasteur expanded its IPV manufacturing facility in France to meet global demand following new WHO supply contracts.

2025: Bilthoven Biologicals received WHO prequalification for its sIPV, facilitating broader global distribution.

Scope of Work – Global Poliovirus Vaccine Inactivated Market

FAQs:

1) What is the current market size of the Global Poliovirus Vaccine Inactivated Market?

The market was valued at USD 1.4 billion in 2023.

2) What is the major growth driver of the Global Poliovirus Vaccine Inactivated Market?

The primary growth driver is the global push for polio eradication through WHO and national immunization programs.

3) Which is the largest region during the forecast period in the Global Poliovirus Vaccine Inactivated Market?

Asia-Pacific was the largest region in 2023 and is expected to remain dominant.

4) Which segment accounted for the largest market share in the Global Poliovirus Vaccine Inactivated Market?

The Public Health Agencies and Government Vaccination Programs segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Poliovirus Vaccine Inactivated Market?

Key players include Sanofi Pasteur, GlaxoSmithKline, Serum Institute of India, AJ Vaccines, and Bilthoven Biologicals.